Research programme: CNS therapeutics - Adamas Pharmaceuticals

Drug Profile

Research programme: CNS therapeutics - Adamas Pharmaceuticals

Alternative Names: ADS-8800; ADS-8801; ADS-9000

Latest Information Update: 07 Sep 2016

Price : $50

At a glance

  • Originator Adamas Pharmaceuticals
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Epilepsy
  • Research CNS disorders

Most Recent Events

  • 07 Sep 2016 Preclinical trials in Epilepsy in USA (unspecified route) prior to September 2016 (Adamas Pharmaceuticals pipeline, September 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top